[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634370":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":68,"collaborators":19,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":19,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":19,"enrollmentInfo":79,"targetDuration":19,"studyType":82,"phases":83,"briefSummary":86,"conditions":87,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Avistone Biotechnology Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ANS02","EXPERIMENTAL","ANS02 capsules, oral administration",[13],"Drug: ANS02",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","4 dose levels would be explored during the study.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Avistone Clinical Study Information Center","CONTACT","8610 84148921","information.center@avistonebio.com",[27,41,52,60],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":19},"Research Site","RECRUITING","Fairfax","Virginia","22031","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-77.30637,38.84622,{"lat":39,"lon":38},{"facility":28,"status":42,"city":43,"state":44,"zip":19,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":51,"contacts":19},"NOT_YET_RECRUITING","Guangzhou","Guangdong","China","CN",{"type":36,"coordinates":48},[49,50],113.25,23.11667,{"lat":50,"lon":49},{"facility":28,"status":42,"city":53,"state":54,"zip":19,"country":45,"countryCode":46,"cosmosGeoPoint":55,"geoPoint":59,"contacts":19},"Harbin","Heilongjiang",{"type":36,"coordinates":56},[57,58],126.65,45.75,{"lat":58,"lon":57},{"facility":28,"status":42,"city":61,"state":62,"zip":19,"country":45,"countryCode":46,"cosmosGeoPoint":63,"geoPoint":67,"contacts":19},"Zhengzhou","Henan",{"type":36,"coordinates":64},[65,66],113.64861,34.75778,{"lat":66,"lon":65},{"type":69,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100634370","phase-1-a-study-to-investigate-ans02-in-participants-with-egfr-mutation-positive-non-small-cell-lung-cancer-100634370",false,"NCT07538804","A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer","A Phase I\u002FII, Open-Label, Multicenter Study to Evaluate the Safety\u002FTolerability, Pharmacokinetics, and Preliminary Efficacy of ANS02 in Participants With EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1\n* Life expectancy ≥ 12 weeks\n* Measurable disease per RECIST v1.1\n* Adequate organ and marrow function as defined in the protocol\n* With documentation of EGFR alteration\n\nExclusion Criteria:\n\n* Active infection including tuberculosis and HBV, HCV or HIV\n* Known active or untreated CNS metastases\n* Participants with carcinomatous meningitis or meningeal metastases, or spinal cord compression\n* Participants with serious cardiovascular or cerebrovascular diseases","ALL","18 Years",{"count":80,"type":81},294,"ESTIMATED","INTERVENTIONAL",[84,85],"PHASE1","PHASE2","This is a first-in-human (FIH) Phase I\u002FII, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.",[88],"Non-Small Cell Lung Cancer","2026-05-20",{"date":91,"type":92},"2026-05-22","ACTUAL",{"date":94,"type":81},"2026-06-09",{"date":96,"type":81},"2029-10-30",{"name":5,"class":6},4]